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Perinatal asphyxia (PA) is associated with dangerous metabolic problems as a result of temporal interruption of oxygen availability.1 Brain injury due to PA is a 
common reason for severe long-term neurological 
deficiency in infants.2 Clinically, this condition is 
referred to as hypoxic ischemic encephalopathy 
(HIE). HIE is the main cause of morbidity and 
mortality in approximately 2% and 60% of full-
term and premature newborns, respectively.3 HIE 
is a serious birth complication in full-term infants, 
and there are few available therapeutic approaches 
to prevent it.4,5 Fetal hypoxia or ischemia is likely 
to manifest in newborns as encephalopathy, and 
may lead to motor or mental disability and even 
death.6–8 During HIE, free radicals are produced (by 
phospholipase activation) within mitochondria9 
causing damage to the brain by attacking membrane 
fatty acids.10,11
HIE activate nitric oxide (NO). Cerebrospinal 
fluid NO levels rise after asphyxia with an increase 
in HIE intensity within one to three days.12 NO 
mediates the cytotoxic activity of macrophages and 
induces cerebral edema.13 Early neuronal NO and late 
inducible NO may trigger cerebral edema, ischemia 
and, subsequently, cell mortality.13,14 Neuronal cell 
death due to HIE happens due to quick cell death by 
glutamate receptor activation. This leads to increased 
sodium entry followed by a passive influx of chloride 
ions disrupting the electrochemical gradient. This is 
followed by a net movement of water into the cells 
causing them to swell and burst (lyse).2 Therapeutic 
mechanisms aim to inhibit the  activity of harmful 
cell processes including reducing the release of 
nitric oxide, free radicals and excitatory amino acid 
neurotransmitters, glutamate, and the induction of 
genes decreasing neuronal cell death.15,16 
Phenobarbital is a neuroprotective agent.17 It 
works by reducing the cerebral blood flow with 
less edema, lowering the cerebral metabolic rate 
and lipid peroxidation in plasma and cerebrospinal 
fluid, scavenging free radicals, and depressing 
glutamate response within the brain.18 A high dose 
of phenobarbital can have a positive influence on the 
outcome of newborns with perinatal asphyxia, but 
larger studies are required to confirm the present 
data.19 
Since very few studies on the impact of 
phenobarbital in infants with PA and the debilitating 
effects of this complication have been conducted, 
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A B S T R AC T
Objectives: Perinatal asphyxia (PA) is very significant in perinatal medicine due to the 
involvement of the central nervous system. This study was conducted to investigate 
the biochemical, clinical, and paraclinical changes associated with phenobarbital 
administration in neonates with PA. Methods: In this prospective, case-control study, 
30 neonates with PA in two groups of 15 each (case and control) were investigated. 
The case group received 20 mg/kg intravenous phenobarbital within six hours of birth, 
and the control group did not receive phenobarbital. Serum concentrations of nitric 
oxide (NO) were measured at enrollment and one week after birth in the two groups. 
Clinical, electroencephalography, and magnetic resonance imaging findings of the two 
groups were compared.  Results: At enrollment, the two groups did not differ in clinical 
severity, seizure incidence, or NO concentration. After one week, NO concentration 
was significantly lower in the case group (p < 0.050), but there was no significant 
difference in other variables between the two groups. Conclusions: Early administration 
of phenobarbital in term neonates with PA could protect them against encephalopathy.
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we sought to evaluate the effect of phenobarbital on 
NO levels in term neonates with PA.
M ET H O D S
In this prospective, case-control study, 30 neonates 
with PA in two groups of 15 each (case and 
control) were studied. the study protocol was 
registered in the Iranian registry of Clinical trials 
(2014090919101N1). 
the inclusion criteria consisted of full-term 
infants with a gestational age ≥ 37 weeks, an Apgar 
score ≤ 5 at 10 minutes after birth or the need 
for resuscitation within 60 minutes after birth, 
and acidosis (base deficit ≥ 16 mmol/l, pH < 7), 
moderate to severe encephalopathy (lethargy, stupor, 
or coma) or hypotonic and abnormal reflexes or 
clinical seizures.20 All infants with maternal diabetes 
mellitus, twin gestation, and congenital abnormalities 
of the central nervous system, chorioamnionitis, 
chromosomal abnormalities, congenital infections, 
and intrauterine growth restriction were excluded 
from the study.21
The infants in the case group received intravenous 
phenobarbital (20 mg/kg) over 60 minutes within 
the first six hours of birth and had their heart rate, 
oxygen saturation, and respiration continuously 
monitored. Neonates in the control group did not 
receive phenobarbital but received similar care. 
Blood samples were obtained to measure NO 
levels shortly after their birth and before any 
intervention from all infants. this process was 
repeated at 14 days in both groups. NO levels were 
determined by spectrophotometry as described by 
Miranda et al.22 
Blood samples were centrifuged for 10 minutes at 
1000 rpm. Serum was separated and stored at - 20°C. 
Plasma samples were deproteinized with ethanol to 
reduce turbidity. The nitrate and nitrite of stable NO 
metabolites, a reliable estimate of NO output in vivo, 
were measured to determine NO levels. These anions 
were detected calorimetrically by Griess reagent. The 
mixture was maintained at room temperature for 30 
minutes following nitrate reduction to nitrite with 
vanadium. The absorbance was measured at 540 nm 
by a double-beam spectrophotometer (Shimatzu 
UV-PC 1601; Shimatzu, Kyoto, Japan). A standard 
curve was obtained by plotting absorbance against 
concentration (µmol/l).
Electroencephalography (EEG) was performed 
at enrollment and repeated at two/three weeks of age 
using a digital computerized apparatus (Neurofax 
EEG-9000; Nihon Kodhen, tokyo, Japan). the 
neurologist who interpreted all EEG results was 
blinded to the clinical data and treatment group.
All infants at 21 days old were transported to 
the magnetic resonance imaging (MrI) unit when 
they were in a clinically stable condition. They were 
accompanied by a pediatrician and monitored with 
pulse oximetry throughout the procedure. Chloral 
hydrate (40 m/kg) was administered orally to sedate 
neonates during the procedure.
Continuous variables were expressed as 
mean±SD and categorical variables as number and 
frequency. the continuous variables were tested 
for normal distribution using the Kolmogorov test. 
The data were analyzed by SPSS Statistics (SPSS 
Statistics, Chicago, US) using the Chi-square test (for 
comparisons between the two groups), exact Fisher’s 
test (for categorical variables), independent t-test or 
Mann-Whitney test (for continuous variables), and 
paired t-test (for comparison between NO levels 
during the intervention). A p-value < 0.050 was 
considered significant.
Table 1: Infant characteristics in case and control groups.
Variable Case Control p-value
Male gender, n (%) 8 (53.3) 8 (53.3) 1.000
Birth weight, g 3252±333 3311±334 0.636
Gestational age, weeks 39.1±0.9 39.2±0.9 0.624
Mothers age, years 25.6±2.9 25.3±3.3 0.506
1 minute Apgar score 2.1±0.8 2.3±0.7 0.567
5 minute Apgar score 6.3±1.1 6.4±1.1 0.870
Natural vaginal  delivery, n (%) 7 (46.7) 8 (53.3) 0.715
HIE (grade 1), n (%) 7 (46.7) 7 (46.7) 1.000
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R E S U LTS
Of the 30 infants in this study, 16 (53.3%) infants 
were male. The gestational age was 38–41 (39.1±0.9) 
weeks. The mean age of mothers was 25.6±2.9 (20–
34) years [table 1]. There was no difference between 
the two groups in gender, birth weight, gestational 
age, mothers’ age, Apgar score, delivery status, and 
HIE grade.
Differences in resuscitation, convulsion, 
bradycardia , meconium, EEG, MrI, and 
hospitalization were not statistically significant in 
the two groups [table 2]. NO levels at day one were 
not significantly different between the two groups, 
but after one week it was significantly lower in the 
case group. NO decreased in both groups after one 
week, but the decrease was significantly higher in the 
case group.
D I S C U S S I O N
The administration of 20 mg/kg of phenobarbital 
decreased serum NO concentration in full-term 
neonates with HIE, but had no effect on clinical, 
EEG, and MrI changes. Infants with HIE have 
higher NO levels compared with healthy control 
infants. In our study, NO at day one was not 
significantly different between the case and control 
group. NO level has been correlated with the 
intensity of cerebral damage in infants with HIE.23,24 
However, in the present study, the intensity of HIE 
was not high. In our study, NO concentration 
decreased significantly within one week in infants 
with HIE who received intravenous phenobarbital, 
which suggested that phenobarbital improves the 
production of endogenous NO.
NO synthase (NOS) catalyzes NO synthesis, 
the oxygenation of arginine in the presence of 
nicotinamide adenine dinucleotide phosphate 
(NADPH) to form nitric oxide, citrulline, and 
NADP+.20 NO plays an important role in the 
pulmonary systemic and cerebral vasodilation and 
is produced in response to increased intracellular 
calcium by endothelial NOS in endothelial cells 
and by neuronal NOS in astrocyte and neurons. A 
NOS inducible isoform produces NO in response to 
cellular stress, which causes neuronal damage when 
converted into secondary reactive nitrogen species 
facilitating nitrosylation reaction and nitration.25
In our study, use of phenobarbital was not 
associated with development of normal EEG 
compared with the control group. In addition, 
clinical seizure was not decreased significantly in 
the case group. These results were inconsistent with 
the results of a previous study where high dose 
phenobarbital in term newborns with severe PA was 
associated with a 27% reduction in the incidence of 
seizures.18 In our study, asphyxia was not severe in all 
neonates. 
Phenobarbital is  believed to exert a 
neuroprotective effect partially by reducing brain 
metabolism and oxygen intake.26 The vasoconstrictive 
effect of phenobarbital declines cerebral edema27 and 
reperfusion injury after the acute phase of asphyxia.28 
However, few clinical trials of barbiturates in 
asphyxiated newborns in developed countries have 
shown marginal or no beneficial results and reported 
remarkable hemodynamic adverse effects.29 In a 
study, early phenobarbital use was associated with a 
three-fold increase in the incidence of later seizures 
in term newborns with PA.30
Table 2: Outcomes variables in the case and control groups. 
Variable Case Control p-value
resuscitation 12 (80.0) 12 (80.0) 1.000
Convulsion 3 (20.0) 5 (33.3) 0.682
Bradycardia 7 (46.7) 5 (33.3) 0.710
Meconium 5 (33.3) 3 (20.0) 0.682
Normal EEG 12 (80.0) 9 (60.0) 0.427
Normal MrI 11 (73.3) 12 (80.0) 1.000
Hospitalization, days 8.6±1.74 10.1±2.4 0.081
NO1 (at day one) 15.3±1.3 14.9±1.4 0.353
NO2 (after one week) 12.9±1.3 14.6±1.3 0.002
NO1-NO2 2.5±0.5 0.3±0.3 < 0.001
EEG: electroencephalography; MRI: magnetic resonance imaging; NO: nitric oxide.
334 A b o lfa zl  K h os h d el ,  et  a l .
O M A N  M E D  J,  V O l  3 1 ,  N O  5 ,  S E P t E M B E r  2 0 1 6
335A b o lfa zl  K h os h d el ,  et  a l .
C O N C LU S I O N
Our study suggested that phenobarbital exerted its 
neuroprotective effects by reducing the formation 
and antagonizing the toxicity of free radicals 
mediated by NO, but it had no effect on seizure, 
duration of hospitalization, clinical findings, and 
changes in EEG and MrI.
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